Numaferm

Numaferm GmbH is a leading biotechnology company focused on strain and process development for peptide and protein production. Founded in 2017 in Düsseldorf, Germany, Numaferm has developed an innovative biochemical platform that enables scalable, cost-effective, and high-quality biomolecule production, meeting both R&D and cGMP standards.
With rapid processes completed within weeks and a strong focus on sustainable approaches, Numaferm accelerates commercial-scale production. At the core of its technology is Numaswitch™, a platform using so-called Switchtags for highly efficient protein expression. The company provides customized solutions, including cell line development, process optimization, scalable peptide and protein production, and commercial cGMP supply through collaborations with CDMOs.
A key proprietary innovation is the Numacut TEV protease, an optimized variant of the Tobacco Etch Virus (TEV) protease. Engineered for enhanced stability, solubility, and cleavage efficiency, Numacut benefits from AI-driven modifications that expand its recognition sequence, improving substrate tolerance for scarless peptide and protein cleavage.
Numaferm is ISO 9001:2015 certified, ensuring superior quality, efficiency, and customer satisfaction. With a track record of over 200 successful peptide and protein projects, the company has earned a reputation as a trusted industry partner. Dedicated to making biomolecules more affordable and accessible, Numaferm serves a wide range of industries, including pharmaceuticals, agriculture, veterinary medicine, generics, and cosmetics, underlining the broad impact of its innovative solutions.

Contact

Numaferm GmbH

Dr. Roland Hecht
Chief Executive Officer

Phone: +49 211 975 32900

E-Mail: info@numaferm.com
Web: https://numaferm.com/

LinkedIn: linkedin.com/numaferm-gmbh